New treatment option for PE

By  |  January 19, 2012 | 

In this large trial of patients with acute symptomatic PE, they all received 5-10 days of LMWH (1mg/kg/dose BID), then 3-6 months of either adjusted dose warfarin, or weekly idrabiotaparinux; the new drug had equivalent risk of recurrent VTE, but lower risk of bleeding at 99 days follow up. This convenient new drug may be an attractive alternative to warfarin, pending FDA approval, and depending on price (abstract)

Leave A Comment

About the Author:

Danielle Scheurer
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Categories

Related Posts

By  | July 2, 2015 |  0
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
By  | September 8, 2014 |  3
  As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
By  | July 6, 2013 |  0
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]